Jobs
View more job listings or post a job
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Exelixis Senior Principal Scientist - DMPK
Post a job

Workshop

Webcast: Conducting Clinical Trials in China – Regulatory and Clinical Challenges and Recent Developments for Drug and Device Development; Lessons for US-based Companies Entering the China Market


Speakers: Lan Huang (BeyondSpring); John Mao (Foresee Pharma); Vivian Mao (Abbott Vascular); Honggang Bi (Covance China); Guobin Wang (PPD China)
Organizers:
Date: 2017-09-21
Time: 14:00-16:30 Pacific Time
Registration fee: (USD):
Location: Online Webcast ONLY
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2017-09-21  (it will close sooner if the seating cap is reached)

About the Topic

Pharmaceutical and Medical Device companies today face a growing demand to expand their clinical trial programs into China in order to access the vast pool of patients. While there are clear benefits for conducting clinical trials in China, there are significant operational and regulatory challenges, which need to be addressed before overseas companies plan to conduct trials in China, either as a trial conducted solely in China or as part of a multinational trial involving Chinese patients. It is important that appropriate measures are put in place to satisfy the ever evolving Chinese clinical trial and approvability standards. In the meantime, the China FDA (CFA) has initiated a major effort to harmonize the regulatory and clinical practices with the developed world and has implemented a number of policies that have profound impact on the clinical and regulatory practices in China.

This workshop aims at discussing some of the regulatory and operational challenges when conducting clinical trials in China, in both, the Pharma and Medical device arena. The presenters who are industry leaders with deep experience with drug and device development in China will review some of the recent regulations for the Pharma and Device development in China and suggest ways to approach China’s FDA (CFDA). It will discuss challenges and solutions when conducting national or multinational device trials in China from the perspectives of a local Chinese CRO as well as global CROs with affiliates in China. The workshop will provide examples for early strategies to include China in the development as part of a global development plan. A case example will demonstrate how a global clinical Phase 3 trial would suffice for a US FDA and China FDA approval.


About the Speakers

Lan Huang, PhD, BeyondSpring (Co-founder & CEO) 
John Mao, PhD, Foresee Pharma (SVP) 
Vivian Mao, MD, Abbott Vascular (Associate Director, Clinical Science) 
Honggang Bi, PhD, Covance China (Corporate Vice President and General Manager) 
Guobin Wang, PhD, PPD China (Director, Project Management)


2024-03-07, [In-Person] Project/Program Management Elevating Drug Development
2024-03-15, [Free Online] Oncology Business Development and Partnering: perspectives and advice from buyers
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-09-10, [In-Person] Translational PK/PD considerations for Novel Modalities
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
©Pharmaceutical & BioScience Society, International; Last Modified: 2/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad